Valuation: PMV Pharmaceuticals, Inc.

Market Cap 102M 91.65M 84.55M 76.51M 143M 9.74B 145M 1.01B 402M 5.1B 384M 376M 16.15B P/E 2026 *
-1.1x
P/E 2027 * -1.48x
Enterprise Value 102M 91.65M 84.55M 76.51M 143M 9.74B 145M 1.01B 402M 5.1B 384M 376M 16.15B EV / Sales 2026 *
-
EV / Sales 2027 * 20.3x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * -
1 day-2.17%
1 week+3.45%
Current month-19.16%
1 month-5.59%
3 months+26.17%
6 months-2.88%
Current year+8.00%
1 week 1.1
Extreme 1.1
1.39
1 month 1.1
Extreme 1.1
1.91
Current year 1.02
Extreme 1.02
1.91
1 year 1.02
Extreme 1.02
1.91
3 years 0.81
Extreme 0.81
3.47
5 years 0.81
Extreme 0.81
25.85
10 years 0.81
Extreme 0.81
63.22
Manager TitleAgeSince
Chief Executive Officer 64 2013-06-30
Director of Finance/CFO 52 2024-01-04
Chief Tech/Sci/R&D Officer - 2022-03-31
Director TitleAgeSince
Director/Board Member 86 2013-05-31
Director/Board Member 64 2013-05-31
Chairman 58 2026-06-03
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Free

Director

84,000 0.1112%
3/5/26 Other

Chief Financial Officer

240,000 0.4510%
3/5/26 Free

Chief Operating Officer

319,270 0.6000%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%+3.45%-4.93%+9.76% 104M
+0.34%+1.12%+34.75%+61.06% 64.14B
+0.98%+2.68%+12.25%+82.98% 55.53B
+1.75%+2.01%+13.30%+103.69% 53.03B
-1.43%-1.17%+26.27%+52.86% 45.99B
-0.48%-2.80%+18.01%+117.99% 42.45B
+0.82%+1.37%+227.94%+922.41% 40.45B
-0.26%-2.57%+12.55%+45.18% 32.25B
-2.07%+42.73%+103.77%+88.74% 34.47B
-2.53%-4.37%+19.74%-13.27% 24.23B
Average -0.53%+4.20%+46.36%+147.14% 39.26B
Weighted average by Cap. -0.08%+3.59%+49.07%+160.37%

Financials

2026 *2027 *
Net sales - 5.03M 4.51M 4.16M 3.76M 7.04M 479M 7.15M 49.61M 19.79M 251M 18.88M 18.48M 794M
Net income -75.59M -67.7M -62.46M -56.52M -106M -7.2B -107M -745M -297M -3.77B -284M -278M -11.93B -78.37M -70.19M -64.76M -58.6M -110M -7.46B -111M -773M -308M -3.91B -294M -288M -12.37B
Net Debt - -
Projected Income Statement - Annual - PMV Pharmaceuticals, Inc.
Logo PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. is a precision oncology company engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor suppressing function. These p53 mutations are found in approximately half of all cancers. The Company is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. In addition to its rezatapopt program, the Company is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets.
Employees
54
Date Price Change Volume
26-10-29 US$1.350 -2.17% 238,113
26-10-28 US$1.380 +10.40% 348,892
26-10-27 US$1.250 +10.62% 375,169
26-10-26 US$1.130 -11.02% 648,579
26-10-23 US$1.270 -2.68% 171,002
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - PMV Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.350USD
Average target price
4.200USD
Spread / Average Target
+211.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PMV Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. PMVP Stock